Clovis Oncology, Inc.

Clovis Oncology, Inc.

Clovis Oncology, Inc.

Overview
Date Founded

2009

Headquarters

5500 Flatiron Parkway,Suite 100,Boulder, CO 80301

Type of Company

Public

Employees (Worldwide)

429

Industries

Pharmaceuticals
Hospitals & Patient Services
Chemicals
Biotechnology

Company Description

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Contact Data
Trying to get in touch with decision makers at Clovis Oncology, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chief Financial Officer & Executive Vice President

Secretary, Executive Vice President & General Counsel

Executive Vice President & Chief Scientific Officer

Executive Vice President of Clinical Development & Pharmacovigilance & Chief Medical Officer

Executive Vice President of Human Resources

Owner

Head of Molecular Diagnostics

Head of Finance

Board of Directors

Vice Chairman at American Diabetes Association Research Foundation, Inc.

Co-Founder at Clovis Oncology, Inc.

Partner at Domain Associates LLC

Founder at Aberdare Ventures

Co-Founder at Versant Venture Management LLC

Former Professional at McKinsey & Co., Inc.

President & Chief Executive Officer at Bellicum Pharmaceuticals Inc.

Founder at X4 Pharmaceuticals, Inc.

Chairman & Chief Executive Officer at Basf Pharma

Director at The Cancer Support Community Valley

Paths to Clovis Oncology, Inc.
Potential Connections via
Relationship Science
You
Clovis Oncology, Inc.
Owners & Shareholders
Details Hidden

Palo Alto Investors, LLC (PAI) is a leading private investment firm. We make long-term investments for high-net-worth and institutional investors based on original, deep, fundamental research. We don’t rent stocks. We own them. With approximately $900 million in assets under management, we offer a diversified micro cap fund and healthcare sector funds. Significant partner ownership in all of our Funds serves to align our financial interests with the financial interests of our clients. At PAI our mission is to deliver superior returns to our clients by investing for the long term. At the core of our investment philosophy lies the belief that intensive, original research is required to discover and evaluate inefficiently priced equities. We generally focus our investments in micro cap and small cap U.S. equities, which are not closely followed by Wall Street sell-side research firms. We target overlooked, misunderstood and undervalued segments of the equity markets, such as healthcare, energy and technology that have significant potential for appreciation. Our experienced research team has extensive industry experience in the sectors they cover. They utilize a disciplined, bottom-up approach to identify promising investments, and the firm’s investment policies ensure liquidity horizons that are sufficient to take advantage of new opportunities. PAI is committed to providing exemplary client service, maintaining the highest level of ethics, operational excellence and professionalism. PAI is independently owned, and has been registered with the SEC since its inception in 1989

Details Hidden

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund firm which focuses primarily on the health care and consumer sectors. They invest predominantly in equities and can be opportunistic across the capital structure. The firm seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated returns. They maintain significant position and portfolio level hedges in an effort to mitigate basis and market risks. Armistice Capital employs a bottom-up analysis, assessing all components of the company’s capital structure and aims to take larger positions where the greatest potential risk adjusted return exists. Armistice Capital’s Domestic Fund and the Offshore Fund, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing in distressed debt, value equities and event equities. In all of its investing activities, the Funds will seek to emphasize capital preservation and will seek to mitigate risk through various hedging strategies at both the position and portfolio levels.

Details Hidden

Ikarian Capital LLC is an American multi -national private company located in Dallas, TX. The firm provides investment advice. It was founded by Neil Tristan Shahrestani.

Recent Transactions
Details Hidden

Clovis Oncology, Inc. issued USD Common Stock

Details Hidden

Clovis Oncology, Inc. issued . USD Common Stock

Details Hidden

Clovis Oncology, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onClovis Oncology, Inc. issued USD Common Stock

Escrow Agent

Advised onClovis Oncology, Inc. issued USD Common Stock

Legal Advisor

Advised onClovis Oncology, Inc. issued USD Common Stock

Legal Advisor

Advised onClovis Oncology, Inc. issued USD Common Stock

Legal Advisor

Advised onClovis Oncology, Inc. issued USD Common Stock

Legal Advisor

Advised onClovis Oncology, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Former Partner at Willkie Farr & Gallagher LLP

Consultant

Chairman & Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine at University of Texas - MD Anderson Cancer Center

Legal Advisor

Partner at Willkie Farr & Gallagher LLP

Key Stats and Financials As of 2020
Market Capitalization
$621M
Total Enterprise Value
$811M
Earnings Per Share
$-4.38
Revenue
$165M
Net Profit
$-369M
EBITDA
$-294M
EBITDAMargin
-178.69%
Total Debt
$647M
Total Equity
$-159M
Enterprise Value / Sales
4.93x
TEVNet Income
-2.2x
Debt TEV
0.8x
Three Year Compounded Annual Growth Rate Of Revenue
43.64%
Non-Profit Donations & Grants
Investors
Details Hidden

Co-Founder at Clovis Oncology, Inc.

Details Hidden

Abingworth is an active, long-term manager which invests exclusively in companies in the life sciences and healthcare sectors including biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics, instrumentation. Their geographic focus is primarily on the US, UK and Europe.The firm seeks to invest USD 15-30 million in small-cap early and late-stage venture, growth equity and public biotechnology companies with strong management and novel technology that offers a significant improvement over current approaches.Abingworth takes minority or majority stakes in their investee companies, seeking to build relationships with management to create world-class companies.They typically hold an investment for three to eight years.

Details Hidden

Frazier Management invests in companies located in the US with an EBITDA of $5 - $50 million. The firm focuses on companies operating in the fields of Life Science, pharmaceuticals and healthcare services. They provides financing for mezzanine, late private/public opportunities, seed, early and later stage, buyouts, recapitalizations and corporate carve-outs with an investment size of $30 - $350 million.

Suppliers
Pfizer, Inc. Medical Support Services | New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Foundation Medicine, Inc. Medical Support Services | Cambridge, MA

Foundation Medicine, Inc. is a molecular information company, which engages in the provision of information on clinical treatment decisions for patients with cancer. The company was founded by Alexis Borisy in 2010 and is headquartered in Cambridge, MA.

Advenchen Laboratories LLC Biotechnology | Moorpark, CA

Advenchen Laboratories LLC operates as a pharmaceutical company. It focuses on pharmaceutical research and development involving small molecule cancer drug discovery programs. The firm’s proprietary drug development product pipeline has demonstrated anti-tumor activities and therapeutic benefits. The company is headquartered in Moorpark, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

BeiGene Ltd. Pharmaceuticals - Beijing, China

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Clovis Oncology, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Clovis Oncology, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Clovis Oncology, Inc..